HIV type 1 subtype A envelope genetic evolution in a slow progressing individual with consistent broadly neutralizing antibodies.

Studies of viruses taken from individuals with broad cross-neutralizing antibodies against primary isolates may reveal novel antibody specificities and their associated epitopes that could be useful for immunogen design. We report on the Env antigenic variability of a slow progressing HIV-1 subtype A-infected donor with consistent broad cross-neutralizing antibodies during the second decade of disease progression after vertical transmission. The Env evolution is characterized by a genetic shift to variants with altered V1-V5 loop sequences, marked by consecutive changes in V1, V4-V5, and C3 and largely conserved V2 and V3 loop sequences. Major V1 Env sequence expansion, variation by a duplication event, and cumulative addition of cysteine residues and potential N-glycosylation sites over time may contribute to escape from antibody pressure directed to Env receptor domains by changing the exposure of neutralization-sensitive epitopes. Conservation of functional epitopes may correlate with the continued presence of broad cross-neutralizing antibodies.

[1]  David C Montefiori,et al.  Measuring HIV neutralization in a luciferase reporter gene assay. , 2009, Methods in molecular biology.

[2]  Steven G. Deeks,et al.  HLA Class I-Restricted T-Cell Responses May Contribute to the Control of Human Immunodeficiency Virus Infection, but Such Responses Are Not Always Necessary for Long-Term Virus Control , 2008, Journal of Virology.

[3]  L. Morris,et al.  The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection , 2007, Journal of Virology.

[4]  L. Stamatatos,et al.  The First Hypervariable Region of the gp120 Env Glycoprotein Defines the Neutralizing Susceptibility of Heterologous Human Immunodeficiency Virus Type 1 Isolates to Neutralizing Antibodies Elicited by the SF162gp140 Immunogen , 2007, Journal of Virology.

[5]  C. Broder,et al.  Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization , 2007, Proceedings of the National Academy of Sciences.

[6]  Douglas D. Richman,et al.  Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors , 2007, Journal of Virology.

[7]  J. Overbaugh,et al.  Human Immunodeficiency Virus Type 1 V1-V2 Envelope Loop Sequences Expand and Add Glycosylation Sites over the Course of Infection, and These Modifications Affect Antibody Neutralization Sensitivity , 2006, Journal of Virology.

[8]  S. Zolla-Pazner,et al.  The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection , 2004, Journal of Virology.

[9]  L. Heyndrickx,et al.  Epitopes corresponding to the envelope genetic subtype are present on the surface of free virions of HIV‐1 group M primary isolates and can be detected in neutralization assays with extended incubation phases , 2003, Journal of medical virology.

[10]  L. Heyndrickx,et al.  Identification and characterization of sera from HIV‐infected individuals with broad cross‐neutralizing activity against group M (env clade A–H) and group O primary HIV‐1 isolates , 2000, Journal of medical virology.

[11]  L. Stamatatos,et al.  V2 Loop Glycosylation of the Human Immunodeficiency Virus Type 1 SF162 Envelope Facilitates Interaction of This Protein with CD4 and CCR5 Receptors and Protects the Virus from Neutralization by Anti-V3 Loop and Anti-CD4 Binding Site Antibodies , 2000, Journal of Virology.

[12]  J. Levy,et al.  Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. , 1998, Blood.

[13]  H. Schuitemaker,et al.  In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. , 1998, The Journal of infectious diseases.

[14]  R. Connor,et al.  Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. , 1995, Virology.

[15]  D. Davis,et al.  Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. , 1990, The Journal of general virology.